InVivo Therapeutics (NVIV) Given Coverage Optimism Rating of 0.19

Media coverage about InVivo Therapeutics (NASDAQ:NVIV) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. InVivo Therapeutics earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.4684744087 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Separately, ValuEngine upgraded shares of InVivo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, April 18th.

Get InVivo Therapeutics alerts:

Shares of NASDAQ:NVIV traded down $0.30 on Friday, hitting $7.56. The stock had a trading volume of 90,612 shares, compared to its average volume of 266,464. InVivo Therapeutics has a twelve month low of $6.25 and a twelve month high of $96.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.20 and a current ratio of 3.20. The company has a market capitalization of $12.30 million, a PE ratio of -0.41 and a beta of 2.47.

InVivo Therapeutics (NASDAQ:NVIV) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($3.25) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($4.00) by $0.75. analysts forecast that InVivo Therapeutics will post -13.88 EPS for the current year.

InVivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.

Insider Buying and Selling by Quarter for InVivo Therapeutics (NASDAQ:NVIV)